Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500...

Repros Therapeutics (RPRX +2.5%) moves up after saying that it's conducting a 6-month 500 subject open label study as part of an FDA requirement for Androxal, and it's sent a "request for guidance" letter to the agency regarding two other pivotal studies on the drug as well. Additionally, the company also says its requested an end of Phase 2 meeting before the end of April for its vaginal Proellex program for the treatment of uterine fibroids.

From other sites
Comments (1)
  • karlis44
    , contributor
    Comments (63) | Send Message
    The biggest problem with clomophene citrate (Clomid) is that the cis-isomer form has negative mood effects and lowers libido. Whether the trans isomer (Androxal) does that I have not seen such in the studies so far. What I have seen are the Testosterone (T) values and sperm counts. If anyone has any mood-libido data on Androxal please contact me. I have treated over 300 men with Clomid to determine functionality of pituitary and as a T replacement. About 65% report negative mood-libido despite elevated T levels which some describe as an Estrogenic-like feeling.
    Let me know.
    Karlis Ullis, MD
    12 Feb 2013, 12:34 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs